SCYNEXIS to Present an Overview of the Company's Pipeline at IDWeek 2018
JERSEY CITY, N.J., Sept. 26, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present an overview of its pipeline at IDWeek 2018, October 3-7, 2018 in San Francisco. The pipeline presentation will take place on Thursday, October 4, 2018 at 2:45 p.m. PT.
SCYNEXIS is developing ibrexafungerp (formerly SCY-078) for the treatment of multiple serious fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis (IC), invasive aspergillosis (IA) and refractory invasive fungal infections. Ibrexafungerp is the first representative of a novel class of structurally distinct glucan synthase inhibitors, triterpenoids. It has demonstrated broad spectrum antifungal activity in vitro and in vivo against multidrug-resistant pathogens, including azole- and echinocandin-resistant strains. Ibrexafungerp also demonstrated high clinical cure and mycological eradication rates in a Phase 2b dose-finding study (the DOVE study) evaluating the oral formulation of the agent for the treatment of VVC. The FDA has granted QIDP and Fast Track designations for both the oral and intravenous formulations of ibrexafungerp for the indications of IC (including candidemia), IA and VVC, and has granted Orphan Drug Designation for the IC and IA indications.
SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. SCYNEXIS's lead product candidate, ibrexafungerp (formerly SCY-078), is a novel oral/IV antifungal agent in Phase 2 clinical and pre-clinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.
George E. MacDougall
MacDougall Biomedical Communications
SOURCE SCYNEXIS, Inc.
Released September 26, 2018